The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s ...

This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy. Nigwekar: ...

A Highland Hospital doctor is debuting a new documentary at ... medical professionals can approach a patient more ...

Adults who were given oral naltrexone at hospital discharge experienced a similar decrease in heavy drinking days as adults given extended-release injectable naltrexone, according to a study published ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Patients with locally advanced head and neck cancer who received ... according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber ...

Abeona Therapeutics' pz-cel gene therapy shows the most durable wound healing in RDEB patients. See why I rate ABEO stock a ...